State Street Corp Vyne Therapeutics Inc. Transaction History

State Street Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.14 - $3.87 $29,406 - $812,878	-210,046 Closed	0 $0
Q2 2022 Aug 15, 2022	BUY	$0.37 - $0.71 $2,294 - $4,402	6,200 Added 3.04%	210,046 $82,000
Q1 2022 May 16, 2022	SELL	$0.5 - $1.15 $170,083 - $391,192	-340,167 Reduced 62.53%	203,846 $133,000
Q3 2021 Nov 15, 2021	BUY	$1.39 - $3.47 $13,065 - $32,618	9,400 Added 1.76%	544,013 $756,000
Q2 2021 Aug 16, 2021	SELL	$3.24 - $6.92 $1.38 Million - $2.94 Million	-424,585 Reduced 44.26%	534,613 $1.88 Million
Q1 2021 May 17, 2021	BUY	$6.34 - $12.68 $6.08 Million - $12.2 Million	959,198 New	959,198 $6.57 Million

36.5K

Ticker VYNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,005,600
Market Cap $179M
Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.